March 23, 2013

$PVCT: Orthogonal

Orthogonality will be a very significant part of Provectus' commercial success because this is how the pharmaceutical industry thinks. Big Pharma wants to combine PV-10 with other drugs, irrespective of whether that is necessary or not. It will take time for industry to understand PV-10 can be used by itself for the majority of of patients, leaving combination treatments only for very late stage disease.

No comments:

Post a Comment